A rather tragic irony that an Australian company with a likely...

A rather tragic irony that an Australian company with a likely treatment for C-19 ARDS saw its trial mishandled by the NIH is the US, when such a treatment, coupled with higher vaccine roll-outs might are clearly the answer to Australian's new predicament - that we are essentially isolated by our own success. Some 55% of the US have had their first vaccination. Over 10% of the population have had COVID-19. They are approching herd immunity and clearly moving on with life with less and less heed paid to COIVD-19.

Governor Cuomo describes New York as "thriving not surviving".

Countries like SIngapore with success similar to Australia are beginning to accpet they must live with some degree of COVID-19 in the community. How easier it would be for Australia to adopt a similar attitude if we had higher vaccination rates and a safety net for the critically ill like Remestemcel-L.